NCT05468736: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years |
|
|
| Active, not recruiting | 2/3 | 3600 | Europe, US, RoW | Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), Placebo, Sodium chloride 0.9% (BP, sterile) | Novavax | COVID-19 | 11/23 | 09/25 | | |
